Cargando…

Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of cardiovascular death in individuals with type 2 diabetes mellitus (T2DM) and cardiovascular disease, but the effect of these inhibitors on early cardiovascular disease remains unknown. This study evaluated the effect of dapagli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Ju-Young, Park, Keun-Young, Kim, Jong-Dai, Hwang, Won-Min, Lim, Dong-Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539345/ https://www.ncbi.nlm.nih.gov/pubmed/32990259 http://dx.doi.org/10.7570/jomes20040

Ejemplares similares

Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21)
por: Hong, Ju-Young, et al.
Publicado: (2021)

Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21)
por: Koo, Bo Kyung
Publicado: (2021)

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2021)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus
por: Lin, Fang-Ju, et al.
Publicado: (2017)

Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure
por: Bao, Nandi, et al.
Publicado: (2023)

L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
por: Shimabukuro, Michio
Publicado: (2023)

Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED)
por: Zainordin, Nur Aisyah, et al.
Publicado: (2019)

Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report
por: Moon, Jae Young, et al.
Publicado: (2021)

Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients
por: Hong, Ju-Young, et al.
Publicado: (2016)

Sensitivity, specificity of biochemical markers for early prediction of endothelial dysfunction in atherosclerotic obese subjects
por: Abulnaja, Khalid O, et al.
Publicado: (2022)

PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs
por: Luan, Jinwen, et al.
Publicado: (2023)

Atherosclerotic Cardiovascular Disease Beginning in Childhood
por: Hong, Young Mi
Publicado: (2010)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
por: Ma, Fei, et al.
Publicado: (2022)

Endothelial dysfunction in diabetes mellitus
por: Hadi, Hadi AR, et al.
Publicado: (2007)

Cardiovascular dysfunction and liver transplantation
por: Kwon, Hye-Mee, et al.
Publicado: (2018)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control
por: Dai, Wenhui, et al.
Publicado: (2022)

Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes
por: Luo, Qianyi, et al.
Publicado: (2022)

Improvement of Endothelial Dysfunction of Berberine in Atherosclerotic Mice and Mechanism Exploring through TMT-Based Proteomics
por: Tan, Wangxiao, et al.
Publicado: (2020)

Retracted: Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
por: Markers, Disease
Publicado: (2023)

Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
por: Kohlmorgen, Christina, et al.
Publicado: (2021)

Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits
por: Münch, Götz, et al.
Publicado: (2012)

The Influence of Calcification Factors and Endothelial-Dysfunction Factors on the Development of Unstable Atherosclerotic Plaques
por: Polonskaya, Yana V., et al.
Publicado: (2020)

The Synthetic Flavonoid Hidrosmin Improves Endothelial Dysfunction and Atherosclerotic Lesions in Diabetic Mice
por: Jiménez-Castilla, Luna, et al.
Publicado: (2022)

Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
por: Shibata, Ryo, et al.
Publicado: (2022)

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
por: Kong, Sung Hye, et al.
Publicado: (2019)

Endothelial dysfunction and cardiovascular disease
por: Widmer, R. Jay, et al.
Publicado: (2014)

Dysfunction and Therapeutic Potential of Endothelial Progenitor Cells in Diabetes Mellitus
por: Hu, Lidong, et al.
Publicado: (2018)

Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care
por: Huh, Youn, et al.
Publicado: (2022)

Correction to: Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
por: Shibata, Ryo, et al.
Publicado: (2022)

Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease
por: Yu, En, et al.
Publicado: (2018)

The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction
por: Luo, Zhi-Chao, et al.
Publicado: (2022)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus
por: van den Oever, Inge A. M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_i4vg56jd4iaetq8pei9mdtsl6h